查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1841961

全球脂質體阿黴素市場：市場規模、佔有率、趨勢分析（按產品、應用、分銷管道和地區）、細分市場預測（2025-2033）

Liposomal Doxorubicin Market Size, Share & Trends Analysis Report By Product, By Application, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 125 Pages | 商品交期: 2-10個工作天內

價格

脂質體阿黴素市場：摘要

預計 2024 年全球脂質體阿黴素市值為 13.1 億美元，到 2033 年將達到 23.8 億美元，2025 年至 2033 年的複合年成長率為 7.04%。

癌症患者，尤其是乳癌患者數量的不斷增加，推動了脂質體阿黴素市場的發展。

奈米技術在創新藥物製劑領域的進步將進一步鞏固這個市場。脂質體製劑正在徹底改變癌症治療，因為它們比傳統製劑更有效、副作用更少。此外，正在進行的旨在改善藥物傳輸和穩定性以及探索新治療應用的研究，也正在推動該市場的快速成長。

癌症診斷數量的增加推動了脂質體阿黴素市場的發展，因為脂質體阿黴素提供標靶化療，副作用更少，正成為首選治療方法。例如，國際癌症研究機構 (IARC) 估計，2022 年新增癌症病例數將達到 2,000 萬，預計到 2050 年將增至 3,500 萬，凸顯了全球癌症負擔的日益加重。

奈米技術在脂質體阿黴素藥物遞送領域的進展正在推動市場發展，並不斷增加對先進脂質體阿黴素製劑的需求。例如，發表在ACS Publications上的一項研究表明，奈米碗載藥的阿黴素脂質體（DOX@NbLipo）對血漿蛋白和血流剪切力表現出較高的抗性，從而最大限度地減少了藥物在遞送至目標組織過程中的滲漏。因此，與其他對照組相比，DOX@NbLipo延長了小鼠的存活期（最長可達50天）。此外，DOX@NbLipo治療使小鼠的壽命延長了108.3%。

針對脂質體阿黴素各種適應症的持續研究正在推動市場發展。例如，發表在《歐洲癌症雜誌》上的一項研究表明，TLD-1（一種新型脂質體阿黴素）在晚期固體癌患者中表現出優於傳統阿黴素製劑的療效。

目錄

第1章 分析方法與範圍

第2章執行摘要

3. 脂質體阿黴素市場：變數、趨勢和範圍

  • 市場聯動展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • 商業環境分析
    • 產業分析：波特五力分析
    • PESTEL分析
    • 管道分析

4. 脂質體阿黴素市場：按產品分類的業務分析

  • 各產品市佔率（2024 年及 2033 年）
  • 產品儀表板
  • 市場規模預測及產品趨勢分析（2021-2033）
  • Doxil/凱利克斯
  • 脂質體
  • Mio 套裝
  • 其他

5. 脂質體阿黴素市場：按應用進行的業務分析

  • 按應用分類的市場佔有率（2024 年和 2033 年）
  • 用於特定目的的儀表板
  • 按應用分類的市場規模預測和趨勢分析（2021-2033）
  • 乳癌
  • 卵巢癌
  • 愛滋病相關卡波西氏肉瘤
  • 多發性骨髓瘤
  • 其他固態腫瘤

6. 脂質體阿黴素市場：按分銷管道進行的業務分析

  • 按分銷管道分類的市場佔有率（2024 年和 2033 年）
  • 分銷通路儀表板
  • 按分銷管道分類的市場規模預測和趨勢分析（2021-2033 年）
  • 醫院藥房
  • 零售藥局
  • 網路藥局

7. 脂質體阿黴素市場：區域估計與趨勢分析

  • 各地區市佔率分析（2024 年及 2033 年）
  • 區域儀表板
  • 市場規模預測及趨勢分析（2021-2033）
  • 北美洲
    • 按國家/地區（2021-2033 年）
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭態勢

  • 參與者概覽
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • Sun Pharmaceutical Industries Ltd.
    • Johnson &Johnson
    • Merck &Co., Inc.
    • Cipla
    • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
    • Lupin
    • Cadila Pharmaceuticals
    • SRS Life Sciences
    • GSK plc
    • Pfizer Inc.
    • Sanofi
    • Sigma-Aldrich Co.
Product Code: GVR-1-68038-743-8

Liposomal Doxorubicin Market Summary

The global liposomal doxorubicin market size was estimated at USD 1.31 billion in 2024 and is projected to reach USD 2.38 billion by 2033, growing at a CAGR of 7.04% from 2025 to 2033. The rising number of cancer cases, particularly breast cancer, fuels the liposomal doxorubicin market.

Advancements in nanotech for innovative drug formulations further strengthen this market. Liposomal delivery revolutionizes cancer treatment by offering increased effectiveness and lower side effects than traditional forms. Furthermore, ongoing research to improve delivery and stability and explore new therapeutic applications propels the market's rapid growth.

Rising cancer diagnoses propel the liposomal doxorubicin market, as it offers targeted chemotherapy with reduced side effects, making it a preferred treatment. For instance, the International Agency for Research on Cancer (IARC) estimates 20 million new cancer cases in 2022, projected to rise to 35 million by 2050, highlighting a growing global cancer burden.

Nano-technological advancements in the drug delivery of liposomal doxorubicin are driving the market by increasing the demand for advanced liposomal doxorubicin formulations. For instance, according to a study published in ACS Publications, Nanobowl-supported liposomal DOX (DOX@NbLipo) is more resistant towards the plasma proteins and blood flow shear force that resulted in minimal drug leakage in the drug delivery at targeted tissue. The study showed that DOX@NbLipo led to prolonged survival of the mice (up to 50 days) compared to other controls. The DOX@NbLipo treatment also led to the biggest increase in the lifespan of the mice by 108.3%.

Ongoing research on liposomal doxorubicin for different indications is propelling the market. For instance, a study published in the European Journal of Cancer demonstrated the higher efficacy of TLD-1 (Novel liposomal doxorubicin) as compared to conventional doxorubicin formulations in patients with advanced solid tumors.

Global Liposomal Doxorubicin Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global liposomal doxorubicin market report based on product, application, distribution channel, and region:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Doxil/Caelyx
  • Lipodox
  • Myocet
  • Others
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Breast Cancer
  • Ovarian Cancer
  • AIDS-related Kaposi's Sarcoma
  • Multiple Myeloma
  • Other Solid Tumors
  • Distribution ChannelOutlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Application
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Liposomal Doxorubicin Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis

Chapter 4. Liposomal Doxorubicin Market: Product Business Analysis

  • 4.1. Product Market Share, 2024 & 2033
  • 4.2. Product Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
  • 4.4. Doxil/Caelyx
    • 4.4.1. Doxil/Caelyx Market, 2021 - 2033 (USD Million)
  • 4.5. Lipodox
    • 4.5.1. Lipodox Market, 2021 - 2033 (USD Million)
  • 4.6. Myocet
    • 4.6.1. Myocet Market, 2021 - 2033 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Liposomal Doxorubicin Market: Application Business Analysis

  • 5.1. Application Market Share, 2024 & 2033
  • 5.2. Application Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
  • 5.4. Breast Cancer
    • 5.4.1. Breast Cancer Market, 2021 - 2033 (USD Million)
  • 5.5. Ovarian Cancer
    • 5.5.1. Ovarian Cancer Market, 2021 - 2033 (USD Million)
  • 5.6. AIDS related Kaposi's Sarcoma
    • 5.6.1. AIDS related Kaposi's Sarcoma Market, 2021 - 2033 (USD Million)
  • 5.7. Multiple Myeloma
    • 5.7.1. Multiple Myeloma Market, 2021 - 2033 (USD Million)
  • 5.8. Other Solid Tumors
    • 5.8.1. Other Solid Tumors Market, 2021 - 2033 (USD Million)

Chapter 6. Liposomal Doxorubicin Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2033
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
  • 6.6. Online Pharmacies
    • 6.6.1. Online Pharmacies Market, 2021 - 2033 (USD Million)

Chapter 7. Liposomal Doxorubicin Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033
  • 7.4. North America
    • 7.4.1. North America Liposomal Doxorubicin Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. U.S. Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. U.S. Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Mexico Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. UK Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Germany Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. France Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Italy Liposomal Doxorubici Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Spain Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Denmark Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Sweden Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Norway Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Japan Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. China Liposomal DoxorubicinMarket Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. India Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Australia Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. South Korea Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Thailand Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Liposomal DoxorubicinMarket Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Japan Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. China Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. South Africa Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Saudi Arabia Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. UAE Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Kuwait Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Sun Pharmaceutical Industries Ltd.
      • 8.5.1.1. Company Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Johnson & Johnson
      • 8.5.2.1. Company Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Merck & Co., Inc.
      • 8.5.3.1. Company Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Cipla
      • 8.5.4.1. Company Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
      • 8.5.5.1. Company Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Lupin
      • 8.5.6.1. Company Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Cadila Pharmaceuticals
      • 8.5.7.1. Company Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. SRS Life Sciences
      • 8.5.8.1. Company Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. GSK plc
      • 8.5.9.1. Company Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Pfizer Inc.
      • 8.5.10.1. Company Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives
    • 8.5.11. Sanofi
      • 8.5.11.1. Company Overview
      • 8.5.11.2. Financial Performance
      • 8.5.11.3. Product Benchmarking
      • 8.5.11.4. Strategic Initiatives
    • 8.5.12. Sigma-Aldrich Co.
      • 8.5.12.1. Company Overview
      • 8.5.12.2. Financial Performance
      • 8.5.12.3. Product Benchmarking
      • 8.5.12.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global liposomal doxorubicin market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global liposomal doxorubicin market, by product, 2021 - 2033 (USD Million)
  • Table 5 Global liposomal doxorubicin market, by application, 2021 - 2033 (USD Million)
  • Table 6 Global liposomal doxorubicin market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 7 North America liposomal doxorubicin market, by country, 2021 - 2033 (USD Million)
  • Table 8 North America liposomal doxorubicin market, by product, 2021 - 2033 (USD Million)
  • Table 9 North America liposomal doxorubicin market, by application, 2021 - 2033 (USD Million)
  • Table 10 North America liposomal doxorubicin market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 11 U.S. liposomal doxorubicin market, by product, 2021 - 2033 (USD Million)
  • Table 12 U.S. liposomal doxorubicin market, by application, 2021 - 2033 (USD Million)
  • Table 13 U.S. liposomal doxorubicin market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 14 Canada liposomal doxorubicin market, by product, 2021 - 2033 (USD Million)
  • Table 15 Canada liposomal doxorubicin market, by application, 2021 - 2033 (USD Million)
  • Table 16 Canada liposomal doxorubicin market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 17 Mexico liposomal doxorubicin market, by product, 2021 - 2033 (USD Million)
  • Table 18 Mexico liposomal doxorubicin market, by application, 2021 - 2033 (USD Million)
  • Table 19 Mexico liposomal doxorubicin market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 20 Europe liposomal doxorubicin market, by country, 2021 - 2033 (USD Million)
  • Table 21 Europe liposomal doxorubicin market, by product, 2021 - 2033 (USD Million)
  • Table 22 Europe liposomal doxorubicin market, by application, 2021 - 2033 (USD Million)
  • Table 23 Europe liposomal doxorubicin market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 24 UK liposomal doxorubicin market, by product, 2021 - 2033 (USD Million)
  • Table 25 UK liposomal doxorubicin market, by application, 2021 - 2033 (USD Million)
  • Table 26 UK liposomal doxorubicin market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 27 Germany liposomal doxorubicin market, by product, 2021 - 2033 (USD Million)
  • Table 28 Germany liposomal doxorubicin market, by application, 2021 - 2033 (USD Million)
  • Table 29 Germany liposomal doxorubicin market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 30 France liposomal doxorubicin market, by product, 2021 - 2033 (USD Million)
  • Table 31 France liposomal doxorubicin market, by application, 2021 - 2033 (USD Million)
  • Table 32 France liposomal doxorubicin market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 33 Italy liposomal doxorubicin market, by product, 2021 - 2033 (USD Million)
  • Table 34 Italy liposomal doxorubicin market, by application, 2021 - 2033 (USD Million)
  • Table 35 Italy liposomal doxorubicin market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 36 Spain liposomal doxorubicin market, by product, 2021 - 2033 (USD Million)
  • Table 37 Spain liposomal doxorubicin market, by application, 2021 - 2033 (USD Million)
  • Table 38 Spain liposomal doxorubicin market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 39 Norway liposomal doxorubicin market, by product, 2021 - 2033 (USD Million)
  • Table 40 Norwa liposomal doxorubicin market, by application, 2021 - 2033 (USD Million)
  • Table 41 Norway liposomal doxorubicin market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 42 Denmark liposomal doxorubicin market, by product, 2021 - 2033 (USD Million)
  • Table 43 Denmark liposomal doxorubicin market, by application, 2021 - 2033 (USD Million)
  • Table 44 Denmark liposomal doxorubicin market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 45 Sweden liposomal doxorubicin market, by product, 2021 - 2033 (USD Million)
  • Table 46 Swede liposomal doxorubicin market, by application, 2021 - 2033 (USD Million)
  • Table 47 Sweden liposomal doxorubicin market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific liposomal doxorubicin market, by country, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific liposomal doxorubicin market, by product, 2021 - 2033 (USD Million)
  • Table 50 Asia Pacific liposomal doxorubicin market, by application, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific liposomal doxorubicin market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 52 Japan liposomal doxorubicin market, by product, 2021 - 2033 (USD Million)
  • Table 53 Japan liposomal doxorubicin market, by application, 2021 - 2033 (USD Million)
  • Table 54 Japan liposomal doxorubicin market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 55 China liposomal doxorubicin market, by product, 2021 - 2033 (USD Million)
  • Table 56 China liposomal doxorubicin market, by application, 2021 - 2033 (USD Million)
  • Table 57 China liposomal doxorubicin market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 58 India liposomal doxorubicin market, by product, 2021 - 2033 (USD Million)
  • Table 59 India liposomal doxorubicin market, by application, 2021 - 2033 (USD Million)
  • Table 60 India liposomal doxorubicin market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 61 Australia liposomal doxorubicin market, by product, 2021 - 2033 (USD Million)
  • Table 62 Australia liposomal doxorubicin market, by application, 2021 - 2033 (USD Million)
  • Table 63 Australia liposomal doxorubicin market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 64 South Korea liposomal doxorubicin market, by product, 2021 - 2033 (USD Million)
  • Table 65 South Korea liposomal doxorubicin market, by application, 2021 - 2033 (USD Million)
  • Table 66 South Korea liposomal doxorubicin market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 67 Thailand liposomal doxorubicin market, by product, 2021 - 2033 (USD Million)
  • Table 68 Thailand liposomal doxorubicin market, by application, 2021 - 2033 (USD Million)
  • Table 69 Thailand liposomal doxorubicin market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 70 Latin America liposomal doxorubicin market, by country, 2021 - 2033 (USD Million)
  • Table 71 Latin America liposomal doxorubicin market, by product, 2021 - 2033 (USD Million)
  • Table 72 Latin America liposomal doxorubicin market, by application, 2021 - 2033 (USD Million)
  • Table 73 Latin America liposomal doxorubicin market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 74 Brazil liposomal doxorubicin market, by product, 2021 - 2033 (USD Million)
  • Table 75 Brazil liposomal doxorubicin market, by application, 2021 - 2033 (USD Million)
  • Table 76 Brazil liposomal doxorubicin market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 77 Argentina liposomal doxorubicin market, by product, 2021 - 2033 (USD Million)
  • Table 78 Argentina liposomal doxorubicin market, by application, 2021 - 2033 (USD Million)
  • Table 79 Argentina liposomal doxorubicin market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 80 Middle East & Africa liposomal doxorubicin market, by country, 2021 - 2033 (USD Million)
  • Table 81 Middle East & Africa liposomal doxorubicin market, by product, 2021 - 2033 (USD Million)
  • Table 82 Middle East & Africa liposomal doxorubicin market, by application, 2021 - 2033 (USD Million)
  • Table 83 Middle East & Africa liposomal doxorubicin market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 84 South Africa liposomal doxorubicin market, by product, 2021 - 2033 (USD Million)
  • Table 85 South Africa liposomal doxorubicin market, by application, 2021 - 2033 (USD Million)
  • Table 86 South Africa liposomal doxorubicin market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia liposomal doxorubicin market, by product, 2021 - 2033 (USD Million)
  • Table 88 Saudi Arabia liposomal doxorubicin market, by application, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia liposomal doxorubicin market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 90 UAE liposomal doxorubicin market, by product, 2021 - 2033 (USD Million)
  • Table 91 UAE liposomal doxorubicin market, by application, 2021 - 2033 (USD Million)
  • Table 92 UAE liposomal doxorubicin market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 93 Kuwait liposomal doxorubicin market, by product, 2021 - 2033 (USD Million)
  • Table 94 Kuwait liposomal doxorubicin market, by application, 2021 - 2033 (USD Million)
  • Table 95 Kuwait liposomal doxorubicin market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Liposomal doxorubicin market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and disease outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Liposomal doxorubicin market dynamics
  • Fig. 12 Liposomal doxorubicin market: Porter's five forces analysis
  • Fig. 13 Liposomal doxorubicin market: PESTLE analysis
  • Fig. 14 Liposomal doxorubicin product market, 2021 - 2033 (USD Million)
  • Fig. 15 Doxil/Caelyx market, 2021 - 2033 (USD Million)
  • Fig. 16 Lipodox market, 2021 - 2033 (USD Million)
  • Fig. 17 Myocet market, 2021 - 2033 (USD Million)
  • Fig. 18 Others market, 2021 - 2033 (USD Million)
  • Fig. 19 Liposomal doxorubicin application market, 2021 - 2033 (USD Million)
  • Fig. 20 Breast cancer market, 2021 - 2033 (USD Million)
  • Fig. 21 Ovarian cancer market, 2021 - 2033 (USD Million)
  • Fig. 22 AIDS related Kaposi's Sarcoma market, 2021 - 2033 (USD Million)
  • Fig. 23 Multiple myeloma market, 2021 - 2033 (USD Million)
  • Fig. 24 Other solid tumors market, 2021 - 2033 (USD Million)
  • Fig. 25 Liposomal doxorubicin distribution channel market, 2021 - 2033 (USD Million)
  • Fig. 26 Hospital pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 27 Retail pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 28 Online pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 29 Liposomal doxorubicin market revenue, by region
  • Fig. 30 Liposomal doxorubicin regional marketplace: Key takeaways
  • Fig. 31 North America liposomal doxorubicin market, 2021 - 2033 (USD Million)
  • Fig. 32 U.S. country dynamics
  • Fig. 33 U.S. liposomal doxorubicin market, 2021 - 2033 (USD Million)
  • Fig. 34 Canada country dynamics
  • Fig. 35 Canada liposomal doxorubicin market, 2021 - 2033 (USD Million)
  • Fig. 36 Mexico country dynamics
  • Fig. 37 Mexico liposomal doxorubicin market, 2021 - 2033 (USD Million)
  • Fig. 38 Europe liposomal doxorubicin market, 2021 - 2033 (USD Million)
  • Fig. 39 UK country dynamics
  • Fig. 40 UK liposomal doxorubicin market, 2021 - 2033 (USD Million)
  • Fig. 41 Germany country dynamics
  • Fig. 42 Germany liposomal doxorubicin market, 2021 - 2033 (USD Million)
  • Fig. 43 France country dynamics
  • Fig. 44 France liposomal doxorubicin market, 2021 - 2033 (USD Million)
  • Fig. 45 Italy country dynamics
  • Fig. 46 Italy liposomal doxorubicin market, 2021 - 2033 (USD Million)
  • Fig. 47 Spain country dynamics
  • Fig. 48 Spain liposomal doxorubicin market, 2021 - 2033 (USD Million)
  • Fig. 49 Norway country dynamics
  • Fig. 50 Norway liposomal doxorubicin market, 2021 - 2033 (USD Million)
  • Fig. 51 Sweden country dynamics
  • Fig. 52 Sweden liposomal doxorubicin market, 2021 - 2033 (USD Million)
  • Fig. 53 Denmark country dynamics
  • Fig. 54 Denmark liposomal doxorubicin market, 2021 - 2033 (USD Million)
  • Fig. 55 Asia Pacific liposomal doxorubicin market, 2021 - 2033 (USD Million)
  • Fig. 56 Japan country dynamics
  • Fig. 57 Japan liposomal doxorubicin market, 2021 - 2033 (USD Million)
  • Fig. 58 China country dynamics
  • Fig. 59 China liposomal doxorubicin market, 2021 - 2033 (USD Million)
  • Fig. 60 India country dynamics
  • Fig. 61 India liposomal doxorubicin market, 2021 - 2033 (USD Million)
  • Fig. 62 Australia country dynamics
  • Fig. 63 Australia liposomal doxorubicin market, 2021 - 2033 (USD Million)
  • Fig. 64 South Korea country dynamics
  • Fig. 65 South Korea liposomal doxorubicin market, 2021 - 2033 (USD Million)
  • Fig. 66 Thailand country dynamics
  • Fig. 67 Thailand liposomal doxorubicin market, 2021 - 2033 (USD Million)
  • Fig. 68 Latin America liposomal doxorubicin market, 2021 - 2033 (USD Million)
  • Fig. 69 Brazil country dynamics
  • Fig. 70 Brazil liposomal doxorubicin market, 2021 - 2033 (USD Million)
  • Fig. 71 Argentina country dynamics
  • Fig. 72 Argentina liposomal doxorubicin market, 2021 - 2033 (USD Million)
  • Fig. 73 MEA liposomal doxorubicin market, 2021 - 2033 (USD Million)
  • Fig. 74 South Africa country dynamics
  • Fig. 75 South Africa liposomal doxorubicin market, 2021 - 2033 (USD Million)
  • Fig. 76 Saudi Arabia country dynamics
  • Fig. 77 Saudi Arabia liposomal doxorubicin market, 2021 - 2033 (USD Million)
  • Fig. 78 UAE country dynamics
  • Fig. 79 UAE liposomal doxorubicin market, 2021 - 2033 (USD Million)
  • Fig. 80 Kuwait country dynamics
  • Fig. 81 Kuwait liposomal doxorubicin market, 2021 - 2033 (USD Million)
  • Fig. 82 Company categorization
  • Fig. 83 Company market position analysis
  • Fig. 84 Strategic framework